Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaAlterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myelomaAdvances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyArsenic trioxide - An old drug rediscovered.Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.Intravenous Vitamin C and Cancer: A Systematic Review.Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway.Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications
P2860
Q24605527-FD8410E3-7FC1-40D9-A5B1-5695E3A0C16DQ28484542-A8A1F5B1-9493-4B5B-955D-8A7C118FEFB7Q33659224-64FC06A0-48E6-4702-8439-20863154D1B7Q33962155-24910571-D92B-49A1-A045-FE1E4F8E9A89Q34054167-1DD4B3C4-67D3-4C39-B4CE-AB94BFF72941Q34458788-AF6F143B-CE4F-4EA1-8473-5D721125C8A4Q35175163-C2F9FC93-C937-4601-AEF5-D5A0C59EBBADQ36693641-3E80D285-FF79-49EB-AF81-F372FF1B80CDQ38253354-B38A984A-7F21-4F34-B698-66233FB62FB8Q41385777-513C3563-145A-4CBC-86C4-FD9A4E817419Q47630577-9E2B8315-448B-4D49-A9B9-CB69CE8A7239Q58742334-3C2F7B1A-B007-4149-9F22-B94E0A1EDE38
P2860
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@ast
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@en
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@nl
type
label
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@ast
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@en
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@nl
prefLabel
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@ast
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@en
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@nl
P2093
P356
P1433
P1476
Efficacy and safety results wi ...... oma patients: a phase 2 trial.
@en
P2093
Esteban Walker
Janice Reed
Mary Ann Karam
Megan Kelly
Mohamad Hussein
Rachid Baz
Rony M Abou-Jawde
Steven Andresen
P2888
P304
P356
10.1385/MO:23:2:263
P577
2006-01-01T00:00:00Z
P6179
1029494115